Ensign Peak Advisors
IBRX icon

Ensign Peak Advisors’s ImmunityBio IBRX Stock Holding History

Ensign Peak Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,150
Closed -$159K – 1702
2024
Q4 		$159K Buy
62,150
+2,500
+4% +$10.4K ﹤0.01% 1699
2024
Q3 		$222K Hold
59,650
– – ﹤0.01% 1690
2024
Q2 		$377K Hold
59,650
– – ﹤0.01% 1660
2024
Q1 		$320K Buy
+59,650
New +$270K ﹤0.01% 1684
2022
Q4 		– Sell
-57,690
Closed -$287K – 1978
2022
Q3 		$287K Sell
57,690
-42,460
-42% -$193K ﹤0.01% 1728
2022
Q2 		$373K Buy
100,150
+79,300
+380% +$319K ﹤0.01% 1581
2022
Q1 		$117K Buy
20,850
+16,290
+357% +$99.9K ﹤0.01% 1997
2021
Q4 		$28K Buy
+4,560
New +$34.3K ﹤0.01% 2172

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ensign Peak Advisors's IBRX Position: Q1 2025 in Review

Ensign Peak Advisors sold out of ImmunityBio (IBRX) in Q1 2025, closing a stake of 62,150 shares — an estimated $159K sold.

Ensign Peak Advisors first reported a position in IBRX in Q4 2021 and held it in 8 quarters. The position peaked at $377K in Q2 2024. 210 funds tracked by Wall St. Rank hold IBRX as of Q1 2025.

  • Ensign Peak Advisors reported no remaining ImmunityBio position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 62,150 ImmunityBio shares in Q1 2025, an estimated $159K.
  • Ensign Peak Advisors first reported a position in ImmunityBio in Q4 2021 and held it in 8 quarters.
  • Ensign Peak Advisors's ImmunityBio position peaked at $377K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.